Tamoxifen-related porphyria cutanea tarda.
We report a case of porphyria cutanea tarda (PCT) in a patient with breast cancer following adjuvant tamoxifen. Cessation of tamoxifen resulted in a prompt decline in urinary porphyrins suggestive of a causative role. Tamoxifen is known to be hepatotoxic; however, its association with PCT is unclear. In this report, we discuss the porphyrinogenicity of tamoxifen and potential mechanisms.
Section of Medicine, Institute of Cancer Research, Sutton, Surrey, United Kingdom. ragarwal@icr.ac.uk
R
R
Agarwal
T J
TJ
Peters
R C
RC
Coombes
D M
DM
Vigushin
D016588:Anticarcinogenic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D008875:Middle Aged; D017119:Porphyria Cutanea Tarda / Q000139:chemically induced* / Q000503:physiopathology; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use
D016588:Anticarcinogenic Agents; D013629:Tamoxifen